Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Teva Pharma +6% ahead of the open after Momenta Pharmaceuticals (MNTA) announced that the FDA issued a warning letter to its contracted Glatopa (glatiramer acetate injection) fill/finish manufacturer (35.20)<p>«The Glatopa 40 mg ANDA remains under regulatory review. The Company believes the application review could be completed at any time. However, under FDA policy, an approval of the application is dependent on the satisfactory resolution of the compliance observations at the Pfizer facility used to make the final product, and Momenta expects that an approval in the first quarter of 2017 is unlikely. Momenta is working with its collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible.»</p><ul><li><em>Glatopa (glatiramer acetate injection) is the generic candidate of Teva's Copaxone</em></li></ul></td> </tr></table>"